Timing and extent of response in colorectal cancer: Critical review of current data and implication for future trials

Oncotarget

Volumn 6, Issue 30, 2015, Pages 28716-28730

  Aprile, Giuseppe ^a   Fontanella, Caterina ^a   Bonotto, Marta ^a   Rihawi, Karim ^a   Lutrino, Stefania Eufemia ^a   Ferrari, Laura ^a   Casagrande, Mariaelena ^a   Ongaro, Elena ^a   Berretta, Massimiliano ^b   Avallone, Antonio ^c   Rosati, Gerardo ^d   Giuliani, Francesco ^e   Fasola, Gianpiero ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d SAN CARLO HOSPITAL   (Italy)

^e NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Colorectal cancer; Deepness of response; Early tumor shrinkage; Endpoint; Response rate

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IPILIMUMAB; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; PD L1 INHIBITOR; REGORAFENIB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ADJUVANT THERAPY; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL RESEARCH; COLON METASTASIS; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DEEPNESS OF RESPONSE; DIGESTIVE SYSTEM CANCER; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; EARLY TUMOR SHRINKAGE; EVIDENCE BASED MEDICINE; GENE MUTATION; HUMAN; METHODOLOGY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OBJECTIVE RESPONSE; ONCOGENE K RAS; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; STANDARDIZATION; TIME-TO-EVENT ENDPOINT; TIME-TO-PROGRESSION; TUMOR NECROSIS; TUMOR VOLUME; BIOASSAY; CLINICAL TRIAL (TOPIC); COLORECTAL NEOPLASMS; DISEASE COURSE; DISEASE FREE SURVIVAL; MORTALITY; PATHOLOGY; PROCEDURES; RISK FACTOR; SURVIVAL ANALYSIS; TIME FACTOR; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; EVIDENCE-BASED MEDICINE; HUMANS; RESEARCH DESIGN; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84945157348     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4747     Document Type: Article

References (86)

1. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics. CA Cancer J Clin. 2014; 64:104-117.
2. Aprile G, Lutrino SE, Ferrari L, Casagrande M, Bonotto M, Ongaro E, Puglisi F. Evidence-based appraisal of the upfront treatment for metastatic unresectable colorectal cancer patients. World J Gastroenterol. 2013; 19:8474-8488.
3. Sobrero AF, Pastorino A, Sargent DJ, Bruzzi P. Raising the bar for antineoplastic agents: how to choose threshold values for superiority trials in advanced solid tumors. Clin Cancer Res. 2014; 21:1036-1043.
4. Liu LY, Yu H, Bai JL, Zeng P, Miao DD, Chen F. Verification of the Correlation between Progression-free Survival and Overall Survival Considering Magnitudes of Survival Post-progression in the Treatment of Four Types of Cancer. Asian Pac J Cancer Prevent. 2015; 16:101-106.
5. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009; 101:1642-1649.
6. Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol. 2007; 25:4562-4568.
7. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014; Jul 12;384:164-72. doi: 10.1016/S0140-6736(13)62422-
8. Berruti A, Amoroso V, Gallo F, Bertaglia V, Simoncini E, Pedersini R, Ferrari L, Bottini A, Bruzzi P, Sormani MP. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. J Clin Oncol. 2014; Dec 1;32:3883-91. doi: 10.1200/JCO.2014.55.2836. Epub 2014 Oct 27.
9. Buyse M, Molenberghs G. Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics. 1998; 54:1014-1029.
10. Ciani O, Davis S, Tappenden P, Garside R, Stein K, Cantrell A, Saad ED, Buyse M, Taylor RS. Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers. Int J Thechnol Assess Health Care. 2014; 30:312-24.
11. Prentice RL. Surrogate and mediating endpoints: current status and future directions. J Natl Cancer Inst. 2009; 101:216-217.
12. Fleming TR, De Mets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996; 125:605-613.
13. Cooper R, Kaanders JH. Biological surrogate end-points in cancer trials: potential uses, benefits and pitfalls. Eur J Cancer. 2005; 41:1261-1266.
14. Sargent D. General and statistical hierarchy of appropriate biologic endpoints. Oncology. 2006; 20:5-9.
15. Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL, Elfring GL, Pignon JP, Piedbois P. Progressionfree survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol. 2007; 25:5218-5224.
16. Giessen C, Laubender RP, Ankerst DP, Stintzing S, Modest DP, Mansmann U, Heinemann V. Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials. Clin Cancer Res. 2013; 19:225-235.
17. Ciani O, Buyse M, Garside R, Peters J, Saad ED, Stein K, Taylor RS. Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer. J Clin Epidemiol. 2015; Mar 6. pii: S0895-4356(15)00113-4. doi: 10.1016/j. jclinepi.2015.02.016. [Epub ahead of print] Review.
18. Panageas KS, LBen-Porat L, Dickler MN, Chapman PB, Schrag D. When You Look Matters: The Effect of Assessment Schedule on Progression-Free Survival. J Natl Cancer Inst. 2007; 99:428-432.
19. Chibaudel B, Bonnetain F, Shi Q, Buyse M, Tournigand C, Sargent DJ, Allegra CJ, Goldberg RM, de Gramont A. Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy-an Aide et Recherche en Cancerologie Digestive Group Study. J Clin Oncol. 2011; 29:4199-4204.
20. Amir E, Seruga B, Kwong R, Tannock IF, Ocaña A. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer? Eur J Cancer. 2012; 48:385-388.
21. Oye RK, Shapiro MF. Reporting results from chemotherapy trials. Does response make a difference in patient survival? JAMA. 1984; 252:2722-2725.
22. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet. 2000; 356:373-378.
23. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989; 8:431-440.
24. Buyse M, Molenberghs G, Paoletti X, Oba K, Alonso A, Van der Elst W, Burzykowski T. Statistical evaluation of surrogate endpoints with examples from cancer clinical trials. Biom J. 2015; Feb 12. doi: 10.1002/bimj.201400049. [Epub ahead of print].
25. Buyse M, Molenberghs G. Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics. 2000; 56:324.
26. Pazdur R. Response rates, survival, and chemotherapy trials. J Natl Cancer Inst. 200; 92:1552-1553.
27. Shindoh J, Loyer EM, Kopetz S, Boonsirikamchai P, Maru DM, Chun YS, Zimmitti G, Curley SA, Charnsangavej C, Aloia TA, Vauthey JN. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol. 2012; 30:4566-4572.
28. Bruzzi P, Del Mastro L, Sormani MP, Bastholt L, Danova M, Focan C, Fountzilas C, Paul C, Rosso R, Venturini M. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol. 2005; 23:5117-25.
29. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981; 47:207-214.
30. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92:205-216.
31. James K, Eisenhauer E, Christian M, Terenziani M, Vena D, Muldal A, Therasse P. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst. 1999; 91:523-528.
32. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version1.1). Eur J Cancer. 2009; 45:228-247.
33. Erasmus JJ, Gladish GW, Broemeling L, Sabloff BS, Truong MT, Herbst RS, Munden RF. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol. 2003; 21:2574-2582.
34. Liu Y, Litière S, de Vries EG, Sargent D, Shankar L, Bogaerts J, Seymour L. The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: results of a survey in the oncology community. Eur J Cancer. 2014; 50:260-266.
35. Villaruz LC, Socinski MA. The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement. Clin Cancer Res. 2013; 19:2629-2636.
36. Korn RL, Crowley JJ. Overview: progression-free survival as an endpoint in clinical trials with solid tumors. Clin Cancer Res. 2013; 19:2607-2612.
37. Rixe O, Fojo T. Is cell death a critical end point for anticancer therapies or is cytostasis sufficient? Clin Cancer Res. 2007; 13:7280-7287.
38. Tirkes T, Hollar MA, Tann M, Kohli MD, Akisik F, Sandrasegaran K. Response criteria in oncologic imaging: review of traditional and new criteria. Radiographics. 2013; 33:1323-1341.
39. Chun YS, Vauthey JN, Boonsirikamchai P, Maru DM, Kopetz S, Palavecino M, Curley SA, Abdalla EK, Kaur H, Charnsangavej C, Loyer EM. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009; 302:2338-2344.
40. Shinagare AB, Jagannathan JP, Kurra V, Urban T, Manola J, Choy E, Demetri GD, George S, Ramaiya NH. Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib. Eur J Cancer. 2014; 50:981-986.
41. Shindoh J, Loyer EM, Kopetz S, Boonsirikamchai P, Maru DM, Chun YS, Zimmitti G, Curley SA, Charnsangavej C, Aloia TA, Vauthey JN. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol. 2012; 30:4566-4572.
42. Chung WS, Park MS, Shin SJ, Baek SE, Kim YE, Choi JY, Kim MJ. Response evaluation in patients with colorectal liver metastases: RECIST version1.1 versus modified CT criteria. AJR Am J Roentgenol. 2012; 199:809-815.
43. Loupakis F, Schirripa M, Caparello C, Funel N, Pollina L, Vasile E, Cremolini C, Salvatore L, Morvillo M, Antoniotti C, Marmorino F, Masi G, Falcone A. Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. Br J Cancer. 2013; 108:2549-2556.
44. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15:7412-7420.
45. Moreno BH, Ribas A. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer. 2015; epub ahead of print.
46. Lu J, Lee-Gabel L, Nadeau MC, Ferencs TM, Soefje SA. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. J Oncol Pharm Pract. 2014; epub ahead of print.
47. Fournier LS, Oudard S, Thiam R, Trinquart L, Banu E, Medioni J, Balvay D, Chatellier G, Frija G, Cuenod CA. Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. Radiology. 2010; 256:511-518.
48. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, Becker A, Adam M, Molls M, Dunst J, Terris DJ, Overgaard J. Prognostic value of tumor oxygenation in 397 head andneck tumors after primary radiation therapy. An International Multi-center Study. Radiother Oncol. 2005; 77:18-24.
49. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009; 50:122S-50S.
50. Nathan PD, Vinayan A, Stott D, Juttla J, Goh V. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther. 2010; 9:15-9.
51. Lastoria S, Piccirillo MC, Caracò C, Nasti G, Aloj L, Arrichiello C, de Lutio di Castelguidone E, Tatangelo F, Ottaiano A, Iaffaioli RV, Izzo F, Romano G, Giordano P, Signoriello S, Gallo C, Perrone F. Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab. J Nucl Med. 2013; Dec 54:2062-9. doi: 10.2967/jnumed.113.119909.
52. Liu FY, Yen TC, Wang JY, Yang TS. Early prediction by 18F-FDG PET/CT for progression-free survival and overall survival in patients with metastatic colorectal cancer receiving third line cetuximab-based therapy. Clin Nucl Med. 2015; Mar 40:200-5.
53. Skougaard K, Nielsen D, Jensen BV, Hendel HW. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab. J Nucl Med. 2013; Jul 54:1026-31. doi: 0.2967/jnumed.112.111757. Epub 2013 Apr 9.
54. Choi M, Kollepara SL, Heilbrun LK, Smith D, Shields AF, Philip PA. PET scans as a predictive marker of survival in advanced colorectal cancer. Clin Colorectal Cancer. 2015; Mar 14:35-40. doi: 10.1016/j.clcc.2014.10.001. Epub 2014 Oct 23. PubMed PMID: 25481195; PubMed Central PMCID: PMC4342990.
55. Tam HH, Cook GJ, Chau I, Drake B, Zerizer I, Du Y, Cunningham D, Koh DM, Chua SS. The Role of Routine Clinical Pretreatment 18F-FDG PET/CT in Predicting Outcome of Colorectal Liver Metastasis. Clin Nucl Med. 2015; May 40:e259-64. doi: 10.1097/RLU.0000000000000744. PubMed PMID: 25742225.
56. Skougaard K, Johannesen HH, Nielsen D, Schou JV, Jensen BV, Høgdall EV, Hendel HW. CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab. Cancer Med. 2014; Oct 3:1294-301. doi: 10.1002/cam4.271. Epub 2014 Jun 18.
57. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007; 25:1753-1759.
58. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008; 100:698-711.
59. Kim MN, Kim BK, Han KH, Kim SU. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. Expert Rev Gastroenterol Hepatol. 2015; 9:335-348.
60. Von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M. German Breast Group. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst. 2008; Apr 16;100:542-51. doi: 10.1093/jnci/djn085.
61. Von Minkwitz D, Mamohudian-Dekordi C, Loibl S, Blohmer JU, Costa SD, Denkert C, et al. Response characteristics and overall survival of 781 patients with triple-negative breast cancer-a meta-analysis on 7 German neoadjuvant studies. Presented at 2013 AACR Annual Meeting, Washington, DC, 6-10th April 2013. Abstract 4699.
62. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008; 19:508-515.
63. Piessevaux H, Buyse M, De Roock W, Prenen H, Schilchting M, Van Cutsem E, Tejpar S. Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial). Ann Oncol. 2009; 20:1375-1382.
64. Piessevaux H, Buyse M, Schlichting M, Van Cutsem C, Bokemeyer C, Heeger S, Tejpar S. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol. 2013; 31:3764-3775.
65. Modest DP, Laubender RP, Stintzing S, Giessen C, Schulz C, Haas M, Mansmann U, Heinemann V. Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial. Acta Oncol. 2013; 52:956-962.
66. Mansmann UR, Laubender RP, Giessen CA, Sartorius U, Heinemann V. Validating the prognostic relevance of initial change in tumor size using a series of therapeutic regimens for patients with metastatic colorectal cancer (mCRC). Presented at: Gastrointestinal Cancers Symposium. San Francisco, CA, USA, 19-21 January 2012.
67. Mansmann UR, Laubender RP, Sartorius U, Giessen CA, Graser A, Heinemann V. Improved early prediction of individual prognosis for patients with mCRC: Joint modeling of tumor shrinkage with volume data for PFS and OS. J Clin Oncol 30. 2012; (suppl; abstr 3603).
68. Sommeijer DW, Shi Q, Meyers JP, Sjoquist KM, Hoff PM, Seymour MT, Cassidy J, Goldberg RM, Douillard JY, Hecht RJ, Hurwitz H, Tournigand C, et al. Prognostic value of early objective tumor response (EOTR) to first-line systemic therapy in metastatic colorectal cancer (mCRC): Individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database. Presented at: ASCO Annual Meeting. Chicago, IL, USA, 31 May-4 June 2013.
69. Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014; 371:1609-1618.
70. Cremolini C, Loupakis F, Antoniotti C, Lonardi S, Masi G, Salvatore L, Cortesi E, Tomasello G, Spadi R, Zaniboni A, Tonini G, Barone C, et al. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann Oncol. 2015; Feb 23. pii: mdv112. [Epub ahead of print].
71. Petrelli F, Pietrantonio F, Cremolini C, Di Bartolomeo M, Coinu A, Lonati V, de Braud F, Barni S. Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: A systematic review and pooled-analysis. Eur J Cancer. 2015; Mar 17. pii: S0959-8049(15)00211-7 [Epub ahead of print].
72. Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai Sy, Ye QH, Yu Y, Xu B, Qin XY, Xu J. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol. 2013; 31:1931-8.
73. Ye LC, Wei Y, Zhu DX, Chen T, Xu J. Impact of early tumor shrinkage on clinical outcome in wild-type-KRAS colorectal liver metastases treated with cetuximab. J Gastroenterol Hepatol. 2015; 30:674-9.
74. Rivera F, Meinolf Karthaus M, J Randolph Hecht R, Gianpiero Fasola G, Jean-Luc Canon JL, Reija Koukakis R, Jan-Henrik Terwey JH, Lee S Schwartzberg LS. First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab (pmab) or bevacizumab (bev) in wild-type (WT) RAS metastatic colorectal carcinoma (mCRC): Tumor response outcomes beyond RECIST. J Clin Oncol 33. 2015; (suppl 3; abstr 660).
75. Giessen C, Laubender RP, Fischer von Weikersthal L. Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial. Cancer Sci. 2013; 104:718-24.
76. Suzuki C, Blomqvist L, Sundin A, Jacobbson H, Bystrom P, Berglund A, Nygren P, Glimelius B. The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Ann Oncol. 2012; 23:948-54.
77. Mansmann UR, Sartorius U, Laubender RP, Clemens Albrecht Giessen CA, Esser R, Heinemann V. Quantitative analysis of the impact of deepness of response on postprogression survival time following first-line treatment in patients with mCRC. Presented at: ASCO Annual Meeting. Chicago, IL, USA, 31 May-June 2013.
78. Moreau P, Attal M, Pégourié B, Planche L, Hulin C, Facon T, Stoppa AM, Fuzibet JG, Grosbois B, Doyen C, Ketterer N, Sebban C, et al. IFM 2005-01 study investigators Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood. 2011; 117:3041-3044.
79. Dytfeld D, Griffith KA, Friedman J, Lebovic D, Harvey C, Kaminski MS, Jakubowiak AJ. Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain-and M-proteinbased model: extended follow-up of a phase II trial. Leuk Lymphoma. 2011; 52:1271-1280.
80. Ahn SY, Jung SH, Joo YD, Lee WS, Lee SM, Choi CW, Kim SJ, Kim K, Lee JJ. Korean Multiple Myeloma Working Party. Early response-based intensification f primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study. Ann Hematol. 2014; 93:1571-1577.
81. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, openlabel, phase 3 trial. Lancet Oncol. 2014; 15:1065-1075.
82. Blagosklonny MV. Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance. Cell Cycle. 2005; Dec 4:1693-8. Epub 2005 Dec15. Review.
83. Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell. 2004; Jan 5:13-7. Review. Erratum in: Cancer Cell. 2004 Oct 6:42.
84. Douillard JY, Siena S, Peeters M, Koukakis R, Terwey JH, Tabernero J. Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer. 2015; May 5. pii: S0959-8049(15)00345-7. doi: 10.1016/j.ejca.2015.03.026. [Epub ahead of print].
85. Gillespie TW. Understanding waterfall plots. J Adv Pract Oncol. 2012; 3:106-11.
86. Shao T, Wang L, Templeton AJ, Jang R, Vera-Badillo FW, McNamara MG, Margolis M, Kim TH, Sinaei M, Shoushtari H, Tannock IF. Use and misuse of waterfall plots. J Natl Cancer Inst. 2014; 106.